Patents by Inventor Christopher N. Boddy
Christopher N. Boddy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10301659Abstract: The present invention relates to the cell-based production of bacterial nonulosonates and their biosynthetic precursors. Specifically, the present invention provides recombinant cells for the production of pseudaminic acid, legionaminic acid, UDP-2,4-diacetamido-2,4,6-trideoxy-?-L-altropyranose, and UDP-2,4-diacetamido-2,4,6-trideoxy-?-D-glucopyranose. Methods for producing the sugars are also provided.Type: GrantFiled: November 17, 2016Date of Patent: May 28, 2019Assignee: National Research Council of CanadaInventors: Dennis M. Whitfield, Susan M. Logan, Ian C. Schoenhofen, Christopher N. Boddy, Benjamin R. Lundgren
-
Publication number: 20170145459Abstract: The present invention relates to the cell-based production of bacterial nonulosonates and their biosynthetic precursors. Specifically, the present invention provides recombinant cells for the production of pseudaminic acid, legionaminic acid, UDP-2,4-diacetamido-2,4,6-trideoxy-?-L-altropyranose, and UDP-2,4-diacetamido-2,4,6-trideoxy-?-D-glucopyranose. Methods for producing the sugars are also provided.Type: ApplicationFiled: November 17, 2016Publication date: May 25, 2017Applicants: National Research Council of Canada, University of OttawaInventors: Dennis M. WHITFIELD, Susan M. LOGAN, Ian C. SCHOENHOFEN, Christopher N. BODDY, Benjamin R. LUNDGREN
-
Patent number: 9512455Abstract: The present invention relates to the cell-based production of bacterial nonulosonates and their biosynthetic precursors. Specifically, the present invention provides recombinant cells for the production of pseudaminic acid, legionaminic acid, UDP-2,4-diacetamido-2,4,6-trideoxy-?-L-altropyranose, and UDP-2,4-diacetamido-2,4,6-trideoxy-?-D-glucopyranose. Methods for producing the sugars are also provided.Type: GrantFiled: July 28, 2014Date of Patent: December 6, 2016Assignees: National Research Council of Canada, University of OttawaInventors: Christopher N. Boddy, Susan M. Logan, Benjamin R. Lundgren, Ian C. Schoenhofen, Dennis M. Whitfield
-
Patent number: 9243240Abstract: A metabolically engineered E. coli strain which produces sialic acid and a method of making said strain. In the engineered E. coli cells, the nanT (sialic acid transporter) and nanA (sialic acid adolase) genes are inactivated, and the neuC and neuB genes of sialic acid biosynthesis in Neisseria meningitidis group B are introduced and overexpressed in the nanT? nanA? E. coli cell. In addition, the glucosamine synthase gene, glmS, of E. coli is co-overexpressed with neuB and neuC.Type: GrantFiled: February 28, 2014Date of Patent: January 26, 2016Assignee: Syracuse UniversityInventors: Christopher N. Boddy, Benjamin R. Lundgren
-
Publication number: 20140356912Abstract: The present invention relates to the the cell-based production of bacterial nonulosonates and their biosynthetic precursors. Specifically, the present invention provides recombinant cells for the production of pseudaminic acid, legionaminic acid, UDP-2,4-diacetamido-2,4,6-trideoxy-?-L-altropyranose, and UDP-2,4-diacetamido-2,4,6-trideoxy-?-D-glucopyranose. Methods for producing the sugars are also provided.Type: ApplicationFiled: July 28, 2014Publication date: December 4, 2014Inventors: Christopher N. Boddy, Susan M. Logan, Benjamin R. Lundgren, Ian C. Schoenhofen, Dennis M. Whitfield
-
Patent number: 8841099Abstract: The present invention relates to the cell-based production of bacterial nonulosonates and their biosynthetic precursors. Specifically, the present invention provides recombinant cells for the production of pseudaminic acid, legionaminic acid, UDP-2,4-diacetamido-2,4,6-trideoxy-?-L-altropyranose, and UDP-2,4-diacetamido-2,4,6-trideoxy-?-D-glucopyranose. Methods for producing the sugars are also provided.Type: GrantFiled: April 20, 2011Date of Patent: September 23, 2014Assignees: National Research Council of Canada, University of OttawaInventors: Christopher N. Boddy, Susan M. Logan, Benjamin R. Lundgren, Ian C. Schoenhofen, Dennis M. Whitfield
-
Publication number: 20140273162Abstract: A metabolically engineered E. coli strain which produces sialic acid and a method of making said strain. In the engineered E. coli cells, the nanT (sialic acid transporter) and nanA (sialic acid adolase) genes are inactivated, and the neuC and neuB genes of sialic acid biosynthesis in Neisseria meningitidis group B are introduced and overexpressed in the nanT? nanA? E. coli cell. In addition, the glucosamine synthase gene, glmS, of E. coli is co-overexpressed with neuB and neuC.Type: ApplicationFiled: February 28, 2014Publication date: September 18, 2014Applicant: SYRACUSE UNIVERSITYInventors: Christopher N. Boddy, Benjamin R. Lundgren
-
Patent number: 8722365Abstract: A metabolically engineered E. coli strain which produces sialic acid and a method of making said strain. In the engineered E. coli cells, the nanT (sialic acid transporter) and nanA (sialic acid adolase) genes are inactivated, and the neuC and neuB genes of sialic acid biosynthesis in Neisseria meningitidis group B are introduced and overexpressed in the nanT? nanA? E. coli cell. In addition, the glucosamine synthase gene, glmS, of E. coli is co-overexpressed with neuB and neuC.Type: GrantFiled: September 26, 2007Date of Patent: May 13, 2014Assignee: Syracuse UniversityInventors: Christopher N. Boddy, Benjamin R. Lundgren
-
Patent number: 8709781Abstract: A system and method for heterologous expression of polyketide biosynthetic pathways from streptomycetes hosts in Escherichia coli for the production and discovery of secondary metabolites. Genomic DNA from Streptomyces rimosus encoding the oxytetracycline biosynthetic pathway is inserted into the genome of the surrogate host Myxococcus xanthus. The M. xanthus transcriptional machinery recognizes and uses the streptomycetes promoter regions to express the biosynthetic enzymes. Co-expression in E. coli of S. rimosus oxytetracycline biosynthesis enzymes and M. xanthus ?54, a key piece of the M. xanthus transcriptional machinery, enables E. coli to recognize and use the promoters from the S. rimosus oxytetracycline biosynthetic pathway, facilitating production of oxytetracycline.Type: GrantFiled: September 23, 2009Date of Patent: April 29, 2014Assignee: Syracuse UniversityInventors: Christopher N. Boddy, Anthony Garza
-
Publication number: 20130196381Abstract: The present invention relates to the cell-based production of bacterial nonulosonates and their biosynthetic precursors. Specifically, the present invention provides recombinant cells for the production of pseudaminic acid, legionaminic acid, UDP-2,4-diacetamido-2,4,6-trideoxy-?-L-altropyranose, and UDP-2,4-diacetamido-2,4,6-trideoxy-?-D-glucopyranose. Methods for producing the sugars are also provided.Type: ApplicationFiled: April 20, 2011Publication date: August 1, 2013Applicants: UNIVERSITY OF OTTAWA, NATIONAL RESEARCH COUNCIL OF CANADAInventors: Christopher N. Boddy, Susan M. Logan, Benjamin R. Lundgren, Ian C. Schoenhofen, Dennis M. Whitfield
-
Publication number: 20100184038Abstract: A system and method for heterologous expression of polyketide biosynthetic pathways from streptomycetes hosts in Escherichia coli for the production and discovery of secondary metabolites. Genomic DNA from Streptomyces rimosus encoding the oxytetracycline biosynthetic pathway is inserted into the genome of the surrogate host Myxococcus xanthus. The M. xanthus transcriptional machinery recognizes and uses the streptomycetes promoter regions to express the biosynthetic enzymes. Co-expression in E. coli of S. rimosus oxytetracycline biosythensis enzymes and M. xanthus ?54, a key piece of the M. xanthus transcriptional machinery, enables E. coli to recognize and use the promoters from the S. rimosus oxytetracycline biosynthetic pathway, facilitating production of oxytetracycline.Type: ApplicationFiled: September 23, 2009Publication date: July 22, 2010Applicant: SYRACUSE UNIVERSITYInventors: Christopher N. Boddy, Anthony Garza
-
Publication number: 20080153133Abstract: A metabolically engineered E. coli strain which produces sialic acid and a method of making said strain. In the engineered E. coli cells, the nanT (sialic acid transporter) and nanA (sialic acid adolase) genes are inactivated, and the neuC and neuB genes of sialic acid biosynthesis in Neisseria meningitidis group B are introduced and overexpressed in the nanT? nanA? E. coli cell. In addition, the glucosamine synthase gene, glmS, of E. coli is co-overexpressed with neuB and neuC.Type: ApplicationFiled: September 26, 2007Publication date: June 26, 2008Applicant: SYRACUSE UNIVERSITYInventors: Christopher N. Boddy, Benjamin R. Lundgren